Is Su Kexin avatrombopag maleate tablets?

Avatrombopag (Avatrombopag) and avatrombopag maleate are actually different names for the same drug. Avatrombopag is an oral thrombopoietin receptor agonist, mainly used to treat idiopathic thrombocytopenia (ITP) and other related diseases. In clinical applications, the name Sucoxin is often used as the trade name of avatropopag maleate tablets.

The mechanism of action of avatrombopag is to activate the thrombopoietin receptor and promote the proliferation and differentiation of megakaryocytes in the bone marrow, thus enhancing the production of platelets. This process can effectively increase platelet counts, improve clinical symptoms and quality of life for patients with thrombocytopenia due to immune response or other factors. Avatrombopag generally exhibits fewer side effects and is better tolerated than traditional treatments, such as steroids.

Clinical trials have shown that avatrombopag is effective in increasing platelet counts, especially when surgery or other medical procedures are required, and can effectively reduce the risk of bleeding. In addition, the use of avatrombopag is relatively flexible. In terms of usage and dosage, avatrombopag tablets should be taken with food, once a day, and continuously for 5 days. Start taking it 10 to 13 days before an elective invasive test or surgery, and choose the recommended dose based on the patient's platelet count.

When using avatrombopag maleate tablets, doctors will closely monitor the patient's platelet count and liver function to ensure the safety and effectiveness of the drug. Although the drug has fewer side effects, it is still necessary to pay attention to possible liver function abnormalities and mild gastrointestinal reactions. Regular monitoring can help identify and deal with potential problems in a timely manner to ensure smooth progress of treatment.